glp-1 iih glp 1 for Efficacy and Safety of GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis - Stefanou - 2025 Large-Scale Study Highlights Therapeutic Benefits

Speaking with our clinic coordinator, Joy, is the fastest and easiest way to talk through your goals, see how Sunrise Health can help, and get started on your journey

Gastrointestinal side effects such as nausea, vomiting, and diarrhoeawhich are common with GLP-1 medicationscan contribute to dehydration, electrolyte imbalances, and general malaise

Founded on a passion for well-being, we formulate our products in the UK, adhering to strict quality standards and eco-friendly practices

The SURPASS program (for type 2 diabetes) and SURMOUNT program (for obesity) together enrolled over 20,000 participants across multiple Phase III trials

Demand Drivers: Increasing Prevalence of Diabetes: The growing global prevalence of type 2 diabetes is a major factor driving the demand for GLP-1 receptor agonists